{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009999","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.290231+00:00","generated_at":"2026-06-17T14:45:40.331552+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytomX FY2022 revenue $53.2M; cash $194M; AbbVie terminates CX-2029; new Moderna/Regeneron deals","bullets":["FY2022 revenue $53.2M (+43% YoY); cash $194M vs $305M at Dec 2021.","Restructuring substantially complete; $7.7M in charges incurred in 2022.","AbbVie terminates CX-2029 collaboration; CytomX regains full rights to CD71 program.","CX-904 Phase 1 dose escalation progressing; IND filings for CX-801 & CX-2051 expected 2H 2023.","New collaborations: Moderna ($35M upfront) and Regeneron ($30M upfront) with up to $1.2B and $2B milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009999","json":"https://secwatch.observer/filing/0000950170-23-009999.json","markdown":"https://secwatch.observer/filing/0000950170-23-009999.md","text":"https://secwatch.observer/filing/0000950170-23-009999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023009999/0000950170-23-009999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023009999/ctmx-20230327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T14:45:40.331552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5cfe7b98d14113e787b6d20f0df3d79a4897850b","claim":"CytomX Therapeutics, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 27, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023009999/0000950170-23-009999-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}